- Home
- SKLZ vs SNTI Comparison
SKLZ vs SNTI Comparison
Compare SKLZ & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- SNTI
- Stock Information
- Founded
- SKLZ 2012
- SNTI 2016
- Country
- SKLZ United States
- SNTI United States
- Employees
- SKLZ N/A
- SNTI N/A
- Industry
- SKLZ EDP Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- SKLZ Technology
- SNTI Health Care
- Exchange
- SKLZ Nasdaq
- SNTI Nasdaq
- Market Cap
- SKLZ 80.3M
- SNTI 85.3M
- IPO Year
- SKLZ N/A
- SNTI N/A
- Fundamental
- Price
- SKLZ $6.23
- SNTI $3.09
- Analyst Decision
- SKLZ Buy
- SNTI Strong Buy
- Analyst Count
- SKLZ 2
- SNTI 1
- Target Price
- SKLZ $10.75
- SNTI $12.00
- AVG Volume (30 Days)
- SKLZ 63.3K
- SNTI 26.4K
- Earning Date
- SKLZ 05-08-2025
- SNTI 05-06-2025
- Dividend Yield
- SKLZ N/A
- SNTI N/A
- EPS Growth
- SKLZ N/A
- SNTI N/A
- EPS
- SKLZ N/A
- SNTI N/A
- Revenue
- SKLZ $92,644,000.00
- SNTI N/A
- Revenue This Year
- SKLZ $0.20
- SNTI N/A
- Revenue Next Year
- SKLZ $14.10
- SNTI N/A
- P/E Ratio
- SKLZ N/A
- SNTI N/A
- Revenue Growth
- SKLZ N/A
- SNTI N/A
- 52 Week Low
- SKLZ $3.54
- SNTI $1.52
- 52 Week High
- SKLZ $7.48
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- SKLZ 59.80
- SNTI 43.14
- Support Level
- SKLZ $6.14
- SNTI $3.03
- Resistance Level
- SKLZ $6.41
- SNTI $3.50
- Average True Range (ATR)
- SKLZ 0.32
- SNTI 0.22
- MACD
- SKLZ -0.04
- SNTI 0.00
- Stochastic Oscillator
- SKLZ 53.28
- SNTI 12.77
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.